Polar Asset Management Partners Inc. Has $7.11 Million Stock Position in Boston Scientific Corporation $BSX

Key Points

• Polar Asset Management Partners Inc. reduced its stake in Boston Scientific Corporation (BSX) by 85.4% in the first quarter, leaving them with 70,517 shares valued at approximately $7.1 million.
• Boston Scientific reported a quarterly EPS of $0.75, exceeding estimates, with a significant year-over-year revenue increase of 22.8% to $5.06 billion.
• Recent analyst reports have increased Boston Scientific's price targets, with Truist Financial raising its target from $120 to $125, and a consensus target price now at $117.50.

Polar Asset Management Partners Inc. lowered its position in Boston Scientific Corporation (NYSE:BSX - Free Report) by 85.4% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 70,517 shares of the medical equipment provider's stock after selling 411,200 shares during the period. Polar Asset Management Partners Inc.'s holdings in Boston Scientific were worth $7,114,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in BSX. GAMMA Investing LLC increased its position in shares of Boston Scientific by 11,720.3% in the 1st quarter. GAMMA Investing LLC now owns 2,577,887 shares of the medical equipment provider's stock valued at $260,057,000 after buying an additional 2,556,078 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Boston Scientific by 18.7% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 10,839,362 shares of the medical equipment provider's stock valued at $968,172,000 after buying an additional 1,709,461 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Boston Scientific by 1.3% in the 1st quarter. Vanguard Group Inc. now owns 134,588,729 shares of the medical equipment provider's stock valued at $13,577,311,000 after buying an additional 1,697,945 shares in the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of Boston Scientific by 18.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 10,610,487 shares of the medical equipment provider's stock valued at $1,070,387,000 after buying an additional 1,664,108 shares in the last quarter. Finally, Assenagon Asset Management S.A. boosted its stake in Boston Scientific by 161.9% in the 1st quarter. Assenagon Asset Management S.A. now owns 2,485,696 shares of the medical equipment provider's stock worth $250,757,000 after purchasing an additional 1,536,663 shares during the period. Institutional investors own 89.07% of the company's stock.

Insider Buying and Selling at Boston Scientific

In other news, Director Edward J. Ludwig sold 4,000 shares of the stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $106.03, for a total transaction of $424,120.00. Following the completion of the transaction, the director directly owned 18,479 shares in the company, valued at $1,959,328.37. This represents a 17.79% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Yoshiaki Fujimori sold 2,901 shares of the firm's stock in a transaction dated Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total transaction of $310,377.99. Following the completion of the sale, the director owned 2,081 shares of the company's stock, valued at $222,646.19. This trade represents a 58.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 174,214 shares of company stock valued at $18,397,457. Corporate insiders own 0.50% of the company's stock.

Analyst Upgrades and Downgrades

BSX has been the subject of a number of research analyst reports. Leerink Partnrs raised shares of Boston Scientific to a "strong-buy" rating in a research note on Monday, June 16th. Jefferies Financial Group reaffirmed a "hold" rating on shares of Boston Scientific in a research note on Monday, July 21st. Morgan Stanley upped their target price on shares of Boston Scientific from $120.00 to $125.00 and gave the stock an "overweight" rating in a research note on Friday, May 16th. Truist Financial upped their target price on shares of Boston Scientific from $120.00 to $125.00 and gave the stock a "buy" rating in a research note on Thursday, July 24th. Finally, Leerink Partners initiated coverage on shares of Boston Scientific in a research note on Monday, June 16th. They issued an "outperform" rating and a $118.00 target price for the company. Three equities research analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and one has given a Hold rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Buy" and an average price target of $117.79.

Boston Scientific Stock Up 0.9%

Shares of Boston Scientific stock traded up $0.92 during trading hours on Monday, reaching $108.14. 7,454,396 shares of the company's stock were exchanged, compared to its average volume of 5,736,611. The company has a 50 day moving average of $104.78 and a two-hundred day moving average of $102.18. Boston Scientific Corporation has a fifty-two week low of $80.64 and a fifty-two week high of $108.94. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. The stock has a market cap of $160.23 billion, a P/E ratio of 64.37, a P/E/G ratio of 2.58 and a beta of 0.65.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping analysts' consensus estimates of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The company had revenue of $5.06 billion during the quarter, compared to the consensus estimate of $4.89 billion. During the same period in the prior year, the business posted $0.62 EPS. The company's quarterly revenue was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, sell-side analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.